Cells deficient in EXD2 show spontaneous chromosomal instability and are sensitive to DNA damage induced by anti-cancer agents such as IR and campthotecin [81], thus EXD2 is a good target for the development of a new anti-tumour treatment. The gene discussed is EXD2; the disease is cancer.